| Jobevne |
761175 |
001 |
351(k) Biosimilar |
bevacizumab-nwgd |
Injection |
Intravenous |
100MG/4ML (25MG/ML) |
Single-Dose Vial |
2025/04/09
|
Biocon Biologics Inc. |
Rx |
Licensed |
bevacizumab |
Avastin |
| Jobevne |
761175 |
002 |
351(k) Biosimilar |
bevacizumab-nwgd |
Injection |
Intravenous |
400MG/16ML (25MG/ML) |
Single-Dose Vial |
2025/04/09
|
Biocon Biologics Inc. |
Rx |
Licensed |
bevacizumab |
Avastin |
| Egrifta WR |
022505 |
003 |
351(a) |
tesamorelin |
For Injection |
Subcutaneous |
11.6MG |
Multi-Dose Vial |
2025/03/25
|
Theratechnologies Inc. |
Rx |
Licensed |
N/A |
N/A |
| Tremfya |
761061 |
006 |
351(a) |
guselkumab |
Injection |
Subcutaneous |
100MG/ML |
Autoinjector |
2025/03/25
|
Janssen Biotech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Conexxence |
761398 |
001 |
351(k) Interchangeable |
denosumab-bnht |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/03/25
|
Fresenius Kabi USA, LLC |
Rx |
Licensed |
denosumab |
Prolia |
| Bomyntra |
761398 |
002 |
351(k) Interchangeable |
denosumab-bnht |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Single-Dose Vial |
2025/03/25
|
Fresenius Kabi USA, LLC |
Rx |
Licensed |
denosumab |
Xgeva |
| Bomyntra |
761398 |
003 |
351(k) Interchangeable |
denosumab-bnht |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Pre-Filled Syringe |
2025/03/25
|
Fresenius Kabi USA, LLC |
Rx |
Licensed |
denosumab |
Xgeva |
| Vyloy |
761365 |
002 |
351(a) |
zolbetuximab-clzb |
Injection |
Intravenous |
300MG |
Single-Dose Vial |
2025/03/24
|
Astellas Pharma US, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Jynneos |
125678 |
002 |
351(a) |
Smallpox and Mpox Vaccine, Live, Non-replicating |
For Injection |
Subcutaneous |
0.5-3.95 X 10E8 INF. U/.5ML |
Single-Dose Vial |
2025/03/21
|
Bavarian Nordic A/S |
Rx |
Licensed |
N/A |
N/A |
| Otulfi |
761379 |
004 |
351(k) Interchangeable |
ustekinumab-aauz |
Injection |
Subcutaneous |
45MG/0.5ML |
Single-Dose Vial |
2025/03/21
|
Fresenius Kabi USA, LLC |
Rx |
Licensed |
ustekinumab |
Stelara |
| Tyenne |
761449 |
001 |
351(k) Biosimilar |
tocilizumab-aazg |
Injection |
Subcutaneous |
162MG/0.9ML |
Pre-Filled Syringe |
2025/03/14
|
Fresenius Kabi USA, LLC |
Rx |
Licensed |
tocilizumab |
Actemra |
| Tyenne |
761449 |
002 |
351(k) Biosimilar |
tocilizumab-aazg |
Injection |
Subcutaneous |
162MG/0.9ML |
Autoinjector |
2025/03/14
|
Fresenius Kabi USA, LLC |
Rx |
Licensed |
tocilizumab |
Actemra |
| Omlyclo |
761399 |
001 |
351(k) Interchangeable |
omalizumab-igec |
Injection |
Subcutaneous |
75MG/0.5ML |
Pre-Filled Syringe |
2025/03/07
|
CELLTRION, Inc. |
Rx |
Licensed |
omalizumab |
Xolair |
| Omlyclo |
761399 |
002 |
351(k) Interchangeable |
omalizumab-igec |
Injection |
Subcutaneous |
150MG/ML |
Pre-Filled Syringe |
2025/03/07
|
CELLTRION, Inc. |
Rx |
Licensed |
omalizumab |
Xolair |
| encelto |
125798 |
001 |
351(a) |
revakinagene taroretcel-lwey |
Implant |
Implantation |
200,000-440,000CELLS/IMPLANT |
Capsule |
2025/03/05
|
Neurotech Pharmaceuticals Inc. |
Rx |
Licensed |
N/A |
N/A |
| TNKase |
103909 |
002 |
351(a) |
tenecteplase |
For Injection |
Intravenous |
25MG |
Single-Dose Vial |
2025/02/28
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Stoboclo |
761404 |
001 |
351(k) Interchangeable |
denosumab-bmwo |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/02/28
|
CELLTRION, Inc. |
Rx |
Licensed |
denosumab |
Prolia |
| Osenvelt |
761404 |
002 |
351(k) Interchangeable |
denosumab-bmwo |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Single-Dose Vial |
2025/02/28
|
CELLTRION, Inc. |
Rx |
Licensed |
denosumab |
Xgeva |
| Glassia |
125325 |
002 |
351(a) |
Alpha-1-Proteinase Inhibitor (Human) |
Injection |
Intravenous |
4G |
Single-Dose Vial |
2025/02/27
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
|
N/A |
| Glassia |
125325 |
003 |
351(a) |
Alpha-1-Proteinase Inhibitor (Human) |
Injection |
Intravenous |
5G |
Single-Dose Vial |
2025/02/27
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
|
N/A |